Angong Niuhuang Pills With Different Bovine Bezoar Formulation Sources in the Treatment of AIS

NCT06883110 | Recruiting

• 1 other identifier: AgNhWinAIS
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a single-center, open-label, controlled clinical trial that prospectively enrolls 100 participants (40 in the Z11020076 group, 40 in the Z20063878 group, and 20 in the blank control group) to collect clinical data, imaging data, and biospecimens over an 84-day follow-up period. The primary objective is to compare the efficacy and safety of Angong Niuhuang Pills from Beijing Tongrentang (Approval No. Z11020076) and Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd. (Approval No. Z20063878) in improving clinical functional outcomes and prognosis in acute ischemic stroke (AIS) patients. The secondary objective is to evaluate the interventional effects of Angong Niuhuang Pills with different bovine bezoar formulation sources on gut microbiota diversity and composition, peripheral blood immune function, and inflammatory status in AIS patients.

Conditions

Acute Ischemic Stroke

Outcome Measures

Primary Outcomes (3)

• modified Rankin Score

  Day 1, Day 7 (±1), Day 14 (±3), and Day 84 (±5)

• NIHSS

  Day 1, Day 7 (±1), Day 14 (±3), and Day 84 (±5)

• 1a score in NIHSS

  Day 1, Day 7 (±1), Day 14 (±3), and Day 84 (±5)

Study Arms (3)

Z11020076 group

EXPERIMENTAL

In addition to receiving standard therapy for acute ischemic stroke (AIS), participants were administered Beijing Tongrentang Angong Niuhuang Pills (3g once daily as a single dose) for 7 consecutive days. Note: The AIS standard therapy strictly adhered to first-line treatments recommended by the Chinese guidelines for acute cerebral infarction management.

Drug: Z11020076

Z20063878 group

EXPERIMENTAL

In addition to receiving standard therapy for acute ischemic stroke (AIS), participants were administered Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd. Angong Niuhuang Pills (3g once daily as a single dose) for 7 consecutive days. Note: The AIS standard therapy strictly adhered to first-line treatments recommended by the Chinese guidelines for acute cerebral infarction management

Drug: Z20063878

blank control group

NO INTERVENTION

Participants would receive AIS standard therapy strictly adhered to first-line treatments recommended by the Chinese guidelines for acute cerebral infarction management

Interventions

Z11020076 DRUG

Beijing Tongrentang Angong Niuhuang Pills (3g once daily as a single dose) for 7 consecutive days.

Z11020076 group

Z20063878 DRUG

Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd. Angong Niuhuang Pills (3g once daily as a single dose) for 7 consecutive days.

Z20063878 group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants or their legal guardians must be capable of understanding the study's purpose and risks and provide informed consent.
• Eligible subjects are aged 18-80 years (inclusive) at the time of consent, regardless of gender.
• All individuals of childbearing potential and male participants must use effective contraception during the study and for at least 6 months after the last dose of the investigational treatment. Additionally, participants must refrain from donating sperm or eggs during the study and for at least 6 months post-treatment.
• Participants must meet traditional Chinese medicine (TCM) diagnostic criteria for stroke (per the Diagnostic and Efficacy Evaluation Standards for Stroke in TCM issued by the State Administration of Traditional Chinese Medicine), including:Primary symptoms: Hemiplegia, altered consciousness, slurred speech or aphasia, sensory disturbance, facial deviation.Secondary symptoms: Headache, dizziness, pupillary abnormalities, dysphagia, gaze deviation, ataxia.Diagnosis requires ≥2 primary symptoms or 1 primary symptom plus ≥2 secondary symptoms. Written informed consent must be obtained.

You may not qualify if:

• Hemorrhagic or mixed stroke.
• Severe cardiac, hepatic, or renal dysfunction or malignancy.
• Prior stroke resulting in a baseline modified Rankin Scale (mRS) score \>3.
• Use of medications judged by the investigator to significantly affect gut microbiota or immune function (e.g., antibiotics, immunosuppressants) during the window period (3 days before baseline to 14±3 days post-treatment).
• Allergy to the investigational product or its components.
• Prior participation in this study.
• Blood donation (≥1 unit) within 90 days, plasma donation within 1 week, or platelet donation within 6 weeks before screening.
• Pregnancy, lactation, or plans for pregnancy/breastfeeding during the study or within 30 days post-treatment.
• Concurrent or recent (within 90 days) participation in other clinical trials.
• Clinically significant suicidal ideation or behavior within the past 12 months per Columbia-Suicide Severity Rating Scale (C-SSRS).
• Inability or unwillingness to comply with protocol requirements.
• Significant hearing/visual impairment, language barriers, claustrophobia, or other conditions interfering with neuropsychological assessments or MRI.
• Any other unspecified reasons deemed by the investigator to disqualify participation.

Sponsors & Collaborators

• Tongji Hospital: lead

Study Sites (1)

Tongji Hospital

Wuhan, Hubei, 430030, China

RECRUITING

MeSH Terms

Conditions

Ischemic Stroke

Condition Hierarchy (Ancestors)

Stroke; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: March 12, 2025
• First Posted: March 19, 2025
• Study Start: September 1, 2025
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: January 12, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)